|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
03320 CHINARES PHARMA
Nominal 
5.550 -0.030 (-0.538%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 244,703,884 | 12.155% | 218,182,994 | 193,611,454 | 168,677,851 | 183,153,157 |
| Cost of Sales | (206,366,398) | 11.813% | (184,563,943) | (164,684,722) | (141,499,042) | (152,679,548) |
| Gross Profit | 38,337,486 | 14.035% | 33,619,051 | 28,926,732 | 27,178,809 | 30,473,609 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 417,106 | 25.505% | 332,341 | 256,395 | 174,089 | 125,788 | |
| Profit / (Loss) before Taxation | 9,880,227 | 18.169% | 8,361,081 | 6,874,689 | 5,954,812 | 5,947,835 | |
| Taxation | (2,105,224) | 23.608% | (1,703,152) | (1,439,805) | (1,474,387) | (1,381,139) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (3,920,756) | 24.167% | (3,157,659) | (2,353,460) | (1,705,534) | (1,622,668) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,854,247 | 10.113% | 3,500,270 | 3,081,423 | 2,774,891 | 2,944,028 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 1,798,626 | 3.829% | 1,732,289 | 1,647,741 | 2,085,093 | 2,755,729 |
| Depreciation & Amortisation | 3,164,365 | 23.683% | 2,558,441 | 2,307,162 | 2,056,937 | 2,118,469 |
| Directors' Emoluments | 8,088 | -27.940% | 11,224 | 10,977 | 7,662 | 9,928 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | 61.000 | 8.929% | 56.000 | 49.056 | 43.764 | 46.582 |
| DPS (cts) | 15.400 | -- | 14.292 | 12.264 | 10.099 | 9.854 |
| Dividend Payout Ratio (%) | 25.246% | -- | 25.522% | 25.000% | 23.077% | 21.154% |
| Cash flow per share ($) | 2.475 | -- | 1.722 | 1.671 | 1.099 | 1.160 |
| NBV per share ($) | 7.315 | -- | 6.933 | 6.635 | 6.225 | 5.803 |
| Remarks: | Real time quote last updated: 13/11/2024 17:08 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 2,604,806 |
| %Change | -2.866% |
| EPS / (LPS) | RMB 0.410 |
| NBV Per Share (¥) | RMB 7.699 |